The effect of combination treatment with casirivimab and imdevimab versus standard antiviral therapy on clinical outcomes in hospitalized COVID-19 patients DOI Creative Commons
Sahar K. Hegazy, Ahmed H. Hassan

Deleted Journal, Journal Year: 2024, Volume and Issue: 1(1)

Published: Oct. 14, 2024

Abstract Background The Coronavirus Disease of 2019 (COVID-19) pandemic motivated research efforts to address this catastrophe from the beginning 2020 present. year 2021 is coming an end, and several developments in pharmacotherapy for COVID-19 have occurred. In terms antiviral therapy, monoclonal antibody combinations become one type immunotherapy. Remdesivir favipiravir are two medications typically used treat COVID-19. Paxlovid (nirmatrelvir plus ritonavir) molnupiravir other agents purpose study was compare effects antibodies (casirivimab imdevimab), remdesivir, on swab results hospitalized patients with at discharge. Methods This a phase IV non-randomized controlled trial (< 300 as sample size) no comparison placebo. study, 265 confirmed by polymerase chain reaction (PCR) indications medication were into three groups ratio (1:2:2): REGN3048-3051 (group A), remdesivir B), C). A nonrandomized single-blind design used. study's provided Hospital Mansoura University. Following ethical approval, conducted approximately 6 months. Results Compared favipiravir, casirivimab imdevimab cause less hepatotoxicity, renal impairment, more negative tested antivirals also had significant adverse effects. All considered safe based these findings. Conclusion result better clinical outcomes. toxicity. Trial registration : Clinicaltrials.gov, NCT05502081, 16/08/2022.

Language: Английский

Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial DOI Creative Commons
Mohammad Bosaeed, Ahmad M. Alharbi, Ebrahim Mahmoud

et al.

Clinical Microbiology and Infection, Journal Year: 2022, Volume and Issue: 28(4), P. 602 - 608

Published: Jan. 11, 2022

To evaluate whether favipiravir reduces the time to viral clearance as documented by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild cases of disease 2019 (COVID-19) compared placebo.

Language: Английский

Citations

89
Recent review of COVID-19 management: diagnosis, treatment and vaccination DOI Open Access
Vivek P. Chavda, Suneetha Vuppu, Toshika Mishra

et al.

Pharmacological Reports, Journal Year: 2022, Volume and Issue: 74(6), P. 1120 - 1148

Published: Oct. 10, 2022

Language: Английский

Citations

55
Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review DOI Creative Commons
Windi Fresha Qomara, Delya Nur Primanissa, Salma Hasni Amalia

et al.

International Journal of General Medicine, Journal Year: 2021, Volume and Issue: Volume 14, P. 8557 - 8571

Published: Nov. 1, 2021

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel strain that causes illnesses known as disease 2019 (COVID-19). Currently, there limited information regarding the therapeutic management for this disease. Several studies have stated antivirals drugs such remdesivir, favipiravir, and lopinavir/ritonavir may potentially inhibit virus from spreading to host. Objective: aim of systematic review was summarize clinical effectiveness safety on COVID-19. Methods: PubMed Cochrane Library databases were searched up July 2021 identify eligible experimental randomized controlled trials COVID-19 patients. This followed Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guideline. Results: From 158 references, 15 included in review. results showed remdesivir has some potential benefits hospitalized patients, seen improvements faster recovery time, less duration hospitalization, fewer side effects among However, impact reducing mortality remains uncertain. Treatment with favipiravir shown promising improvement status although suggested no significant differences parameters length hospitalizations recovery. A combination other supportive therapy more favorable outcomes Furthermore, use patients reported compared standard care notable adverse effect reactions. Conclusion: study provides an overview evidence-based role thorough assessment benefit-risk profile urgently needed. current based very available data; therefore, further well-designed are required. Keywords: COVID-19, antiviral drugs, SARS-CoV-2, lopinavir/ritonavir,

Language: Английский

Citations

53
Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force DOI Creative Commons
Ho Lee, Shotaro Chubachi, Ho Namkoong

et al.

BMC Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(1)

Published: Dec. 12, 2022

We aimed to elucidate differences in the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization Japan, by COVID-19 waves, from conventional strains Delta variant.We used secondary data a database and performed retrospective cohort study that included 3261 aged ≥ 18 years enrolled 78 hospitals participated Japan Task Force between February 2020 September 2021.Patients hospitalized during second (mean age, 53.2 [standard deviation {SD}, ± 18.9]) fifth 50.7 [SD 13.9]) waves had lower mean age than those other waves. Patients first wave longer hospital stay (mean, 30.3 days 21.5], p < 0.0001), post-hospitalization complications, such as bacterial infections (21.3%, were also noticeable. In addition, there was an increase use drugs remdesivir/baricitinib/tocilizumab/steroids latter wave, exhibited greater number presenting symptoms, higher percentage required oxygen therapy at time admission. However, invasive mechanical ventilation highest mortality rate third wave.We identified clinical each up Japan. The associated severity on admission, rate, ventilation.

Language: Английский

Citations

38
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study DOI
Rujipas Sirijatuphat, Weerawat Manosuthi, Suvimol Niyomnaitham

et al.

Emerging Microbes & Infections, Journal Year: 2022, Volume and Issue: 11(1), P. 2197 - 2206

Published: Aug. 23, 2022

We investigated Favipiravir (FPV) efficacy in mild cases of COVID-19 without pneumonia and its effects towards viral clearance, clinical condition, risk development. PCR-confirmed SARS-CoV-2-infected patients were enrolled (2:1) within 10 days symptomatic onset into FPV control arms. The former received 1800 mg twice-daily (BID) on Day 1 800 BID 5-14 thereafter until negative detection, while the latter only supportive care. primary endpoint was time to improvement, defined by a National Early Warning Score (NEWS) ≤1. 62 (41 female) comprised arm (median age: 32 years, median BMI: 22 kg/m²) 31 (19 28 kg/m²). sustained NEWS, 2 14 for arms, respectively (adjusted hazard ratio (aHR) 2.77, 95% CI 1.57-4.88, P < .001). also had significantly higher likelihoods improvement after enrolment NEWS (79% vs. 32% respectively, 8 (12.9%) 7 (22.6%) arms developed at (range) 6.5 (1-13) treatment, (P = .316). All recovered well complications. can conclude that early treatment associated with faster improvement.Trial registration: Thai Clinical Trials Registry identifier: TCTR20200514001.

Language: Английский

Citations

26
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment DOI Open Access
Gokben Sahin, Özlem Akbal Dağıstan, Meltem Culha

et al.

Journal of Pharmaceutical Sciences, Journal Year: 2022, Volume and Issue: 111(10), P. 2652 - 2661

Published: June 9, 2022

Language: Английский

Citations

25
Drugs for COVID-19: An Update DOI Creative Commons
Jessica Ceramella, Domenico Iacopetta, Maria Stefania Sinicropi

et al.

Molecules, Journal Year: 2022, Volume and Issue: 27(23), P. 8562 - 8562

Published: Dec. 5, 2022

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh known human coronavirus, and it identified in Wuhan, Hubei province, China, 2020. It caused highly contagious disease called 2019 (COVID-19), declared a global pandemic by World Health Organization (WHO) on 11 March A great number of studies search new therapies vaccines have been carried out these three long years, producing series successes; however, need for more effective vaccines, other solutions is still being pursued. This review represents tracking shot current pharmacological used treatment COVID-19.

Language: Английский

Citations

23
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update DOI Creative Commons
Md. Easin Mia,

Mithu Howlader,

Farzana Akter

et al.

Clinical Pathology, Journal Year: 2024, Volume and Issue: 17

Published: Jan. 1, 2024

The COVID-19 pandemic-led worldwide healthcare crisis necessitates prompt societal, ecological, and medical efforts to stop or reduce the rising number of fatalities. Numerous mRNA based vaccines for viral vectors have been licensed use in emergencies which showed 90% 95% efficacy preventing SARS-CoV-2 infection. However, safety issues, vaccine reluctance, skepticism remain major concerns making mass vaccination a successful approach treat COVID-19. Hence, alternative therapeutics is needed eradicating global burden from developed low-resource countries. Repurposing current medications drug candidates could be more viable option treating as these therapies previously passed significant checkpoints development patient care. Besides vaccines, this review focused on potential usage therapeutic agents including antiviral, antiparasitic, antibacterial drugs, protease inhibitors, neuraminidase monoclonal antibodies that are currently undergoing preclinical clinical investigations assess their effectiveness treatment Among repurposed remdesivir considered most promising agent, while favipiravir, molnupiravir, paxlovid, lopinavir/ritonavir exhibited improved effects terms elimination viruses. outcomes with oseltamivir, umifenovir, disulfiram, teicoplanin, ivermectin were not significant. It noteworthy combining multiple drugs therapy showcases impressive managing individuals Tocilizumab presently employed patients who exhibit COVID-19-related pneumonia. antiviral such galidesivir, griffithsin, thapsigargin under trials severe symptoms. Supportive may involve corticosteroids, convalescent plasma, stem cells, pooled antibodies, vitamins, natural substances. This study provides an updated progress crucial guide inventing novel interventions against

Language: Английский

Citations

5
The equivocal healthcare market in Bangladesh during the COVID‐19 pandemic: Policy, politics and life DOI Open Access
Nur Newaz Khan

The Australian Journal of Anthropology, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Abstract Drawing on 14 months of ethnographic research in Bangladesh, I analyse how the COVID‐19 pandemic intersected with global and local healthcare markets 2020 to shape public health governance affecting interests, needs, lives. In early phase, misuse administrative power corruption among bureaucrats, government representatives, political leaders became apparent Bangladesh. It fostered private catastrophes, exposing some fraudulence medical equipment provision treatment disease. Due state's denial, citizens were deprived low‐cost solutions (e.g. rapid antigen test kits) for infection detection. Engaging concept disaster capitalism, argue that elusive role state, politicised ground governance, medicine market combined sectors ultimately benefited corporations rather than urgent needs Bangladeshis.

Language: Английский

Citations

0
Modeling the Enzymatic Mechanism of the SARS-CoV-2 RNA-Dependent RNA Polymerase by DFT/MM-MD: An Unusual Active Site Leading to High Replication Rates DOI
Emmanuelle Bignon, Antonio Monari

Journal of Chemical Information and Modeling, Journal Year: 2022, Volume and Issue: 62(17), P. 4261 - 4269

Published: Aug. 19, 2022

Viral infection relies on the hijacking of cellular machineries to enforce reproduction infecting virus and its subsequent diffusion. In this context, replication viral genome is a key step performed by specific enzymes, i.e., polymerases. The SARS-CoV-2, causative agent COVID-19 pandemics, based duplication RNA genome, an action RNA-dependent polymerase. contribution, using highly demanding DFT/MM-MD computations coupled 2D-umbrella sampling techniques, we have determined chemical mechanisms leading inclusion nucleotide in nascent strand. These results highlight high efficiency polymerase, which lowers activation free energy less than 10 kcal/mol. Furthermore, SARS-CoV-2 polymerase active site slightly different from those usually found other similar particular, it lacks possibility proton shuttle via nearby histidine. Our simulations show that absence partially compensated lysine whose assists reaction, opening up alternative, but efficient, reactive channel. present first mechanistic resolution at level shed light unusual enzymatic reactivity paving way for future rational design antivirals targeting emerging viruses.

Language: Английский

Citations

16